Scarica l'app Stockscreener
3.65
6.41%
-0.25
Dopo l'orario di chiusura:
3.65
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Diamedica Therapeutics Inc Borsa (DMAC) Ultime notizie
DiaMedica Therapeutics Insiders Up US$4.1m On US$9.00m Investment - simplywall.st
Millennium Management LLC Increases Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
42,212 Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Purchased by Jane Street Group LLC - Defense World
Can DiaMedica Deliver A Breakthrough In Preeclampsia Treatment? - RTTNews
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Increases By 38.3% - Defense World
Lake Street Keeps Their Buy Rating on Diamedica Therapeutics (DMAC) - The Globe and Mail
Northern Trust Corp Has $978,000 Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DMAC: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus
DiaMedica Therapeutics’ (DMAC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright holds DiaMedica stock Buy rating, $10 target - Investing.com
H.C. Wainwright holds DiaMedica stock Buy rating, $10 target By Investing.com - Investing.com India
Transcript : DiaMedica Therapeutics Inc.Special Call - marketscreener.com
With 39% ownership, DiaMedica Therapeutics Inc. (NASDAQ:DMAC) insiders have a lot riding on the company's future - Yahoo Finance
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 - BioSpace
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 | DMAC Stock News - GuruFocus
14,581 Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Purchased by Balyasny Asset Management L.P. - Defense World
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on D - GuruFocus
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia - Business Wire
Research Analysts Offer Predictions for DMAC FY2025 Earnings - Defense World
Equities Analysts Offer Predictions for DMAC FY2029 Earnings - Defense World
DiaMedica targets preeclampsia Phase 2 dose selection and ReMEDy2 interim analysis in H1 2026 as enrollment momentum builds - MSN
Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail
Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC) - The Globe and Mail
DiaMedica Therapeutics reports annual meeting results By Investing.com - Investing.com Nigeria
DiaMedica Therapeutics reports annual meeting results - Investing.com
DiaMedica Elects Directors at Annual Meeting - TipRanks
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2025 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Inc (DMAC) Q1 2025 Earnings Call Highlights: Strong Financial Position ... - Yahoo Finance
DiaMedica Therapeutics Inc (DMAC) Q1 2025 Earnings Call Highligh - GuruFocus
DiaMedica Therapeutics Reports Q1 2025 Financials and Trial Progress - TipRanks
DiaMedica Therapeutics Announces Poster Presentation at European - GuruFocus
DiaMedica Therapeutics Announces Poster Presentation At European Stroke Organisation ConferenceESOC 2025 - marketscreener.com
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference -- ESOC 2025 | DMAC Stock News - GuruFocus
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025 - Business Wire
DiaMedica (DMAC) Awaits Key Phase 2 Study Results for Preeclamps - GuruFocus
Earnings call transcript: DiaMedica Therapeutics Q1 2025 earnings beat expectations By Investing.com - Investing.com India
Transcript : DiaMedica Therapeutics Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
Earnings call transcript: DiaMedica Therapeutics Q1 2025 earnings beat expectations - Investing.com Australia
Barclays PLC Takes Position in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
Raymond James Financial Inc. Makes New Investment in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights - BioSpace
DiaMedica Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
DiaMedica Therapeutics Reports Q1 2025 Financial Results and Clinical Progress - TipRanks
DiaMedica Therapeutics Reports First Quarter 2025 Financial Resu - GuruFocus
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights | DMAC Stock News - GuruFocus
DiaMedica Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Susquehanna International Group LLP Grows Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - The AM Reporter
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May - BioSpace
How To Trade (DMAC) - news.stocktradersdaily.com
DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025 - BioSpace
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):